Blood flows through every organ in the body. On its journey it collects vital information from each one of those organs. This information from blood is paramount in detecting early-stage cancer. The HrC Test has been developed to target an array of biomarkers that are always present in blood. To what degree they are present is what determines if cancer is absent or present. This information may be used to help accelerate a cancer diagnosis, and improve a prognosis through early access to treatment.
PLEASE NOTE THIS TEST IS CURRENTLY ONLY AVAILABLE AT LONDON MEDICAL LABORATORY (MON-THURS 1.30-5pm) AND IS NOT SUITABLE FOR UNDER 18s OR PREGNANT WOMEN.
Next Generation Sequencing (NGS) technology is a revolutionary method for analyzing RNA and DNA to uncover genetic variations associated with diseases, such as cancer.
Our Three-Pronged Approach:
-
Whole Exome Sequencing: Focuses on sequencing protein-coding genes to detect DNA mutations commonly associated with cancer.
-
Whole Transcriptome Sequencing: Targets the same genes but analyzes RNA to study gene expression, identifying changes that indicate cancer.
-
HrC Technology: Developed by scientists at Epigeneres Biotech, this method examines very small embryonic-like stem cells (VSELs) for epigenetic changes that transform them into Cancer Stem Cells. These cells enter the bloodstream, and their activity levels increase along with cancer risk.
HrC Score: Combining these methods, we analyze the data to produce the HrC Score, reflecting the likelihood and timing of cancer development. The score is interpreted using a proprietary scale, indicating risk levels from none to high.
Please Note: HrC Genomics does not diagnose cancer (as biposy is the current approved method for this) but provides an indication of cancer risk which may help accelerate a cancer diagnosis and more favorable prognosis. If you have symptoms of cancer, please see your GP immediately.
